| Similar Articles |
|---|
 |
The Motley Fool
March 21, 2007
Brian Lawler |
InterMune Slims Down InterMune announces changes after its lead compound fails in a study. Investors, take note.   |
The Motley Fool
December 26, 2006
Brian Lawler |
InterMune's Secret Drug Surprise Shares of InterMune have risen after positive trial results for one of its top drug candidates. Investors, take note. |
The Motley Fool
April 30, 2004
Charly Travers |
Sales Weakness From InterMune Biotechnology company InterMune would seem to be in good shape with a drug, Actimmune (which helps boost the immune system of cancer patients and others). The drug, however, has been showing quarterly sales weakness since early 2003, a trend that now seems like it may continue into the future. |
The Motley Fool
March 10, 2010
Brian Orelli |
Up 160% With Room to Run You've got to love biotech and InterMune. |
The Motley Fool
January 10, 2011
Brian Orelli |
By the Way, We Need to Run Another Trial InterMune has decided to run a new trial to gain U.S. approval on its idiopathic pulmonary fibrosis drug. |
The Motley Fool
March 19, 2008
Brian Lawler |
InterMune Suffers a Postscript The former CEO is indicted, but that shouldn't hurt the drugmaker. |
The Motley Fool
February 3, 2009
Brian Orelli |
InterMune Batting .500 The results weren't exactly what Rule Breakers pick InterMune was looking for, but things could have been worse -- and the stock is up 38% today on the news. |
The Motley Fool
October 7, 2010
Brian Orelli |
Asset Sold, Questions Begin Why did InterMune sells its stake in danoprevir? |
The Motley Fool
December 17, 2010
Brian Orelli |
An Overnight Double: Santa Visits InterMune in Europe The Committee for Medicinal Products for Human Use issued a positive recommendation for the approval of InterMune's idiopathic pulmonary fibrosis treatment, Esbriet, sending shares up 140%. |
The Motley Fool
March 8, 2010
Brian Orelli |
Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting. |
The Motley Fool
January 3, 2011
Brian Orelli |
Clinical Trial Results Fail to Inspire Inspire Pharma gets cut in half after a cystic fibrosis trial failure. |
The Motley Fool
October 30, 2006
Brian Lawler |
InterMune Plays "Let's Make a Deal" The biopharmaceutical 's deal with Roche could mean stiff competition for rival Vertex. Investors, take note. |
The Motley Fool
August 9, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
December 31, 2010
Brian Orelli |
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. |
The Motley Fool
September 6, 2007
Brian Lawler |
Foolish Fantasy Football: InterMune on Special Teams This stock analyst chooses developmental stage drugmaker InterMune as his speculative bet. |
Chemistry World
August 29, 2014
Sarah Houlton |
Roche to buy InterMune for respiratory boost Roche is to acquire InterMune in a deal worth $8.3 billion. |
The Motley Fool
September 27, 2006
Brian Lawler |
One Step Forward for InterMune The company's lead drug will enter phase 1 trials, bringing potential good fortune to investors. |
The Motley Fool
December 29, 2006
Brian Lawler |
InterMune Gets Ready to Sell Shares For investors' sake, getting any necessary dilution over and done with at higher share prices means fewer shares of the diluting financing need to be issued, so it's smart that InterMune is getting ready to sell shares now in case more positive clinical trial results cause shares to spike. |
The Motley Fool
July 24, 2007
Brian Lawler |
Discounting InterMune Shares of InterMune fall after analyst worries about one of its drugs. Investors looking to buy into the next blockbuster class of hepatitis C treatments on the cheap just got their chance. |
The Motley Fool
July 25, 2011
Brian Orelli |
Bristol-Myers' Acquisition Could Pay for Itself It will gain access to potential milestones. |
Pharmaceutical Executive
April 1, 2011 |
Off-Label But On Point? Use of off-label drugs is a balancing act for physicians, and poses even more problems for pharma. The FDA is moving slowly to help. |
The Motley Fool
May 3, 2010
Brian Orelli |
While You Were Reveling in Dendreon's Win The FDA has approved Vimovo, an arthritis drug from Pozen and AstraZeneca, and Bristol-Myers Squibb also got a decision from the FDA, but it wasn't the positive kind. |
The Motley Fool
December 20, 2010
Brian Orelli |
A Good Fit. On the Surface. Digging a little deeper into Gilead's acquisition of Arresto. |
The Motley Fool
March 11, 2010
Jim Mueller |
Is Medivation a Buy? What is the thinking with regards to Medivation today? It already got a big haircut last week. Is it worth investing in at these lower prices? |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
The Motley Fool
January 8, 2008
Brian Lawler |
InterMune Goes Step by Step The company updates investors on the progress of its lead drug for hepatitis C. |
The Motley Fool
April 3, 2008
Brian Lawler |
Will InterMune's Hepatitis C Drug Compete? InterMune announces positive data for its hepatitis C treatment drug. |
The Motley Fool
January 31, 2011
Brian Orelli |
5 Drugmakers Headed Back to the Drawing Board Sometimes an FDA rejection is more of a to-do list. |
The Motley Fool
January 5, 2012
Brian Orelli |
Are These Biotech Drug Launches Back on Track? With the annual health-care conference starting up next week, Dendreon and InterMune announced preliminary fourth-quarter sales today. |
The Motley Fool
December 15, 2011
David Williamson |
1 Massive Biotech Bloodbath Trial results and FDA panels ruled the health-care sector today. |
The Motley Fool
March 4, 2011
Brian Orelli |
Up 15% for That? InterMune investors react to a non-event. |
The Motley Fool
October 30, 2009
Brian Orelli |
Earnings? Yawn. Trial Data? Moving! For Human Genome Sciences investors, the anticipation is frightening. |
The Motley Fool
November 22, 2006
Brian Lawler |
How to Market a Drug Too Well Cephalon's promotion of its pain drug Actiq might have crossed the line. |
The Motley Fool
May 20, 2010
Brian Orelli |
FDA Transparency! A Big Win for Investors The Food and Drug Administration has possibly just made things easier for investors. Let's just hope drug companies don't shoot it down. |
Chemistry World
July 3, 2014
Andy Extance |
EMA wrangles restrain trial data progress Tempers are being tested as the pharmaceutical industry's journey towards transparency on clinical trial data enters a critical phase. |
